Atropine Sulfate Ophthalmic Ointment, 1% (Sterile) Rx only

Manufacturer
AvPAK
Effective date
2022-01-17
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
legacy-cache
Hydrated at
2026-08-01 22:16:10

Label at a glance#

ProductAtropine Sulfate
Active ingredientATROPINE SULFATE
Label structure12 sections

Indications and uses

For mydriasis and/or cycloplegia. For cycloplegic refraction, for pupillary dilation desired in inflammatory conditions of the iris and uveal tract.

Dosage and administration

Apply a small amount of ointment to the conjunctival sac once or twice a day, or as directed by a physician. FOR OPHTHALMIC USE ONLY

Label contents#

Full prescribing information#

DESCRIPTION:

DESCRIPTION SECTION

 Atropine Sulfate Ophthalmic Ointment, 1% is a sterile topical anticholinergic for ophthalmic use. The active ingredient is represented by the chemical structural formula:

chem_structure.jpg
chem_structure.jpg

(C 17H 23NO 3) 2•H 2SO 4•H 2O                                                                     
Mol. Wt. 694.83

Chemical Name:

Benzeneacetic acid, α-(hydroxymethyl)-, 8-methyl-8-azabicyclo-[3.2.1]oct-3-yl ester, endo-(±)-, sulfate (2:1) (salt), monohydrate.

Each gram contains:

ACTIVE: Atropine Sulfate, 1% (10 mg); INACTIVES: Lanolin oil, mineral oil, purified water, and white petrolatum.

CHEMICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The anticholinergic effect of this product blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia).

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For mydriasis and/or cycloplegia. For cycloplegic refraction, for pupillary dilation desired in inflammatory conditions of the iris and uveal tract.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

This product should not be used in patients with primary glaucoma or a predisposition to narrow anterior chamber angle glaucoma.

This product should not be used in pediatric patients who have previously had a severe systemic reaction to atropine. This product should not be used in those persons showing hypersensitivity to any component of this preparation.

WARNINGS

WARNINGS SECTION

In pediatric patients, use with extreme caution. Excessive use in pediatric patients or in certain individuals with a previous history of susceptibility to belladonna alkaloids may produce systemic symptoms of atropine poisoning. If this occurs, discontinue medication and use appropriate therapy as outlined in OVERDOSAGE.

PRECAUTIONS

PRECAUTIONS SECTION

To avoid excessive systemic absorption, the lacrimal sac should be compressed by digital pressure for two to three minutes after instillation. To avoid inducing angle closure glaucoma, an estimation of the depth of the angle of the anterior chamber should be made. Administration of atropine in infants requires great caution.

Patient Warning:

GENERAL PRECAUTIONS SECTION

Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated. Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation.


Parents should be warned not to get this preparation in their children’s mouth and to wash their own hands and the child’s hands following administration.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No studies have been conducted in animals or in humans to evaluate the potential of these effects.

Animal reproduction studies have not been performed with atropine. It is also not known whether atropine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Atropine should be given to pregnant women only if clearly needed.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Prolonged use may produce local irritation characterized by follicular conjunctivitis, vascular congestion, edema, exudate, and an eczematoid dermatitis. Severe reactions are manifested by hypotension with progressive respiratory depression. Coma and death have been reported in the very young.

To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

OVERDOSAGE SECTION

Systemic atropine toxicity is manifested by flushing and dryness of the skin (a rash may be present in pediatric patients), blurred vision, a rapid and irregular pulse, fever, abdominal distension in infants, mental aberration (hallucinosis) and loss of neuromuscular coordination.


Atropine poisoning, although distressing, is rarely fatal, even with large doses of atropine, and is self-limited if the cause is recognized and the atropine medication is discontinued. In severe intoxication, physostigmine salicylate may be administered parenterally to provide more prompt relief of the intoxication. Give physostigmine salicylate as 1-5 mL IV of dilution containing 1 mg in 5 mL of saline. The smaller dose is for pediatric patients, and injection should take not less than 2 minutes. EKG control is advisable. Dosage can be repeated every 5 minutes up to a total dose of 2 mg in pediatric patients and 6 mg in adults every 30 minutes. Physostigmine is contraindicated in hypotensive reactions. Atropine (1 mg) should be available for immediate injection if physostigmine causes bradycardia, convulsions or bronchoconstriction. In pediatric patients, the body surface must be kept moist.


Use extreme caution when employing short-acting barbiturates to control excitement.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Apply a small amount of ointment to the conjunctival sac once or twice a day, or as directed by a physician.


FOR OPHTHALMIC USE ONLY

HOW SUPPLIED

HOW SUPPLIED SECTION

Atropine Sulfate Ophthalmic Ointment, 1% is supplied in an ophthalmic tip applicator tube in the following size:

3.5 g tubes - NDC 50268-118-35

0000

STORAGE:

SPL UNCLASSIFIED SECTION

Store between 15° to 25°C (59° to 77°F).

Manufactured for:

AvKARE

Pulaski, TN 38478

AV 07/20

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

cartoncarton

FDA-Initiated Inactive NDC Indexing#

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
50268-118-35GM - Gram50268-1186d055970-0050-47fe-91f4-6139f47bced512021-02-05

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
50268-11850268-118-35

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
28eed024-f3bc-b00e-e063-6294a90aafc5b46872ae-6647-6590-e053-2a95a90a75ef2024-12-10Warnings, Adverse reactionsExact identifier
spl set id: b46872ae-6647-6590-e053-2a95a90a75ef

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.